JD Supra: Mergers
JUNE 10, 2025
Ropes & Gray attended the SuperReturn International conference in Berlin last week, which attracted over 5,500 decision makers from the private markets industry who came together to share their outlook for 2025 and beyond.
JD Supra: Mergers
AUGUST 7, 2025
In this edition of UK Equity Capital Markets Insights, we cover the following developments: • Consultation by the UK Takeover Panel on IPO Disclosures and Dual Class Share Structures - • The Publication of the UK FCA’s Final Rules on the Public Offers and Admissions to Trading Regime - • The Publication of the UK Digitisation Taskforce’s Final Report (..)
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
JD Supra: Mergers
JANUARY 10, 2025
A variety of factors are expected to significantly increase Canadian M&A activity in 2025. We expect to enter 2025 with some positive momentum in Canadian dealmaking.
JD Supra: Mergers
JUNE 24, 2025
In its first application of the policy on voluntary self-disclosures (“VSDs”) in connection with mergers and acquisitions (“M&A”), on June 16, 2025, the US Department of Justice’s (“DOJ”) National Security Division (“NSD”) announced that it had declined to prosecute a US private equity firm after it voluntarily disclosed criminal violations of (..)
JD Supra: Mergers
JULY 11, 2025
On 3 July 2025, the UK Takeover Panel (Panel) published a new Practice Statement 36 (PS 36), which provides formal guidance on how the Panel will interpret and apply the Takeover Code to an “unlisted share alternative” (known as stub equity) in the context of a take-private transaction of a UK public company.
JD Supra: Mergers
APRIL 25, 2025
private equity market. Read our latest insights into the U.S. We cover monthly deal activity and size, fundraising, exits, leveraged loans, and a look ahead. The drop in March deal count pushed Q1 deal count to the lowest quarterly level since the onset of the pandemic in Q2 2020.
JD Supra: Mergers
JUNE 19, 2025
As of mid-2025, private equity (PE) investors remain intensely interested in health care services and technology companies despite higher borrowing costs, heightened regulatory scrutiny, and an increasingly complex state review landscape. By: ArentFox Schiff
Expert insights. Personalized for you.
Let's personalize your content